$Nuwellis(NUWE.US) dumped -61%, triggered by a $3.4 million market order issuance at $2.59 per share, just after it completed a 1-for-35 reverse stock split in late June.

The ultrafiltration treatment device itself has clinical value; the issue lies in the financing rhythm—first splitting shares to maintain listing status, then immediately issuing shares at a low price, effectively returning the price propped up by the split back to where it started.

This dilemma is typical for micro-cap medical device stocks: products are still in the ramp-up phase, cash flow cannot sustain profitability, and existing shareholders face repeated dilution. Whether the devices sell well or not is not the primary contradiction for the stock price in the short term—before cash flow turns positive, how many more rounds of this repeated dilution will there be? 😥